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Abstract We investigated the possible modulation of the
intestinal contractility by uracil nucleotides (UTP and
UDP), using as model the murine small intestine. Contrac-
tile activity of a mouse ileum longitudinal muscle was
examined in vitro as changes in isometric tension. Tran-
scripts encoding for uracil-sensitive receptors was investi-
gated by RT-PCR. UDP induced muscular contractions,
sensitive to PPADS, suramin, or MRS 2578, P2Y6 receptor
antagonist, and mimicked by PSB 0474, P2Y6-receptor
agonist. UTP induced biphasic effects characterized by an
early inhibition of the spontaneous contractile activity
followed by muscular contraction. UTP excitatory effects
were antagonized by PPADS, suramin, but not by MRS
2578, whilst the inhibitory effects were antagonized by
PPADS but not by suramin or MRS 2578. UTPγS, P2Y2/4
receptor agonist but not 2-thio-UTP, P2Y2 receptor agonist,
mimicked UTP effects. The inhibitory effects induced by
UTP was abolished by ATP desensitization and increased
by extracellular acidification. UDP or UTP responses were
insensitive to TTX, atropine, or L-NAME antagonized by
U-73122, inhibitor of phospholipase C (PLC) and pre-
served in the presence of nifedipine or low Ca2+ solution.
Transcripts encoding the uracil nucleotide-preferring recep-
tors were expressed in mouse ileum. Functional postjunc-
tional uracil-sensitive receptors are present in the
longitudinal muscle of the mouse ileum. Activation of
P2Y6 receptors induces muscular contraction, whilst acti-
vation of P2Y4 receptors leads to inhibition of the
contractile activity. Indeed, the presence of atypical UTP-
sensitive receptors leading to muscular contraction is
suggested. All uracil-sensitive receptors are linked to the
PLC pathway.
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Introduction
Nucleotides, such as, ATP, ADP, UTP, and UDP are
important extracellular signaling molecules, activating cell
membrane receptors, designed as P2 receptors, subdivided
into two large families, ionotropic P2X and G-coupled P2Y
receptors. So far, seven mammalian P2X-receptor subtypes
(P2X1-7) and eight mammalian P2Y-receptors subtypes
(P2Y1,2,4,6,11,12,13,14) have been cloned and recognized.
P2X receptors are ligand-gated ion channels activated by
ATP. Indeed, P2Y receptors can be subdivided into (1)
adenine nucleotide-preferring receptors mainly responding
to ADP and ATP; (2) uracil nucleotide-preferring receptors;
(3) receptors of mixed selectivity; and (4) receptors
responding to the sugar nucleotides UDP–glucose and
UDP–galactose [1]. In particular, ADP is the most potent
physiological agonist at humans and rodents P2Y1, P2Y12,
and P2Y13 receptors, whilst ATP is the agonist at the
human P2Y11 receptor (although this receptor may be
activated by UTP). UTP is an agonist for P2Y2 and P2Y4
receptors, whilst UDP is agonist for P2Y6 receptors. UTP is
up to two orders of magnitude more potent than UDP at
P2Y2 and P2Y4 receptors, while the reverse is true at P2Y6
receptors. Indeed, P2Y2 receptors are activated by both
UTP and ATP, and in rodents (rats and mice), differently
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from the human orthologues, P2Y4 receptors are equally
activated by UTP and ATP. Lastly, P2Y14 receptors
initially considered to be activated solely by UDP–sugar
derivatives can be also activated by UDP [2–4]. Although
considerable progress has been done, most of the P2Y
receptor subtypes are still lacking potent and selective
synthetic agonists and antagonists. Thus, a combined use
of subtype preferential agonists and antagonists may allow
the pharmacological characterization of a P2Y subtype.
Moreover, some of the orphan P2Y-like receptors are still
waiting for deorphanization.
So far, adenine-based purines have been mainly studied
as regulators of gastrointestinal physiology [5]; however,
other nucleotides, such as, uridine triphosphate (UTP), are
released in the extracellular space, and they can be
endogenous ligands for the uracil nucleotide-preferring
receptors, which have reported to be widely distributed in
the intestine [6]. It is suggested that purinergic signaling
pathways, via activation of uracil nucleotide-preferring
receptors, contribute to the regulation of ion transport in
the intestinal, biliary, and pancreatic duct epithelium [7].
P2Y2 and P2Y4 receptors are prevalent luminal receptors
[8], whilst basolateral P2Y6 receptors have been shown in
colonic epithelia cells to stimulate NaCl secretion [9].
Previous studies suggested that pyrimidines may also
modulate gastrointestinal motility. UTP has been reported
to induce muscular contractile responses in the rat proximal
stomach [10], duodenum [11], rat colon muscularis muco-
sae [12], whilst a relaxant response has been shown in a rat
distal colon due to activation of neuronal P2Y2 receptors
and nitric oxide release [13]. UTP relaxant responses have
been shown also in a mouse distal colon [14]. In addition,
P2Y4 receptors are suggested to be the main functional
receptor underlying the purinergic neuron-to-glia signaling
in the enteric nervous system [15, 16].
Due to the scarce information on the physiological
function of the pyrimidines as modulators of gastroin-
testinal motor activity and in consideration that extra-
cellular nucleotides and their receptors have been
implicated in the pathogenesis of inflammatory bowel
disease [17], we aimed to investigate the possible
modulation of the intestinal contractility by uracil nucleo-
tides (UTP and UDP), and the P2Y receptor subtype(s)
involved, using as model the murine small intestine, in
which the functionality of the adenine nucleotide-
preferring receptors has been established [18–20].
Methods
Experiments, authorized by the Ministero della Sanità
(Rome, Italy), were performed on adult male mice
(C57BL/10SnJ; 25.5±0.5-g body weight; 15 weeks old),
obtained from Charles River Laboratories, Calco-Lecco,
Italy) and maintained in a light (12-h/12-h light) and
temperature (23°C)-controlled environment with free
access to food and water. The animals were sacrificed
by cervical dislocation; the abdomen was immediately
opened, the ileum was removed and placed in Krebs
solution, and the contents of the excised segments were
gently flushed out. Segments (20 mm in length) were
suspended in a four-channel organ bath containing
10 ml of oxygenated (95% O2 and 5% CO2) Krebs
solution maintained at 37°C.
Recording of mechanical activity
The distal end of each segment was tied to an organ holder,
and the proximal end was secured with a silk thread to an
isometric force transducer (FORT 10, Ugo Basile, Biolog-
ical Research Apparatus, Comerio VA, Italy). Mechanical
activity was amplified and digitized via an analog/digital
interface (Quad Bridge and PowerLab/400, AD Instru-
ments, Ugo Basile, Biological Research Apparatus,
Comerio VA, Italy) and then acquired onto a personal
computer. Longitudinal preparations were subjected to an
initial tension of 200 mg (unless otherwise stated) and were
allowed to equilibrate for at least 30 min. Rhythmic
spontaneous contractions of varying amplitude developed
in all preparations. After the equilibration time, prepa-
rations were challenged with 10 μM of carbachol until
reproducible responses were obtained. The amplitude of
the contractile response to carbachol was 968.2±
64.1 mg (n=20). Moreover, preparations were challenged
with 1 μM isoproterenol for 2 min, to verify if they were
able to relax. The amplitude of the relaxant response to
isoprotenerol was 216.2±21.3 mg (n=20). Since activa-
tion of P2 receptors can be controlled by ecto-
nucleotidases capable of hydrolyzing nucleoside tri- and
diphosphates [21], UDP and UTP were tested in the
continued presence of the ecto-nucleotidase inhibitor
ARL67156 (30 μM).
Concentration–response curves for uracil nucleotides or
related drugs were constructed by noncumulative addition
of the drug. The contact time between tissue and agonist
was 3 min, which was followed by two washings with
1 min between each wash. Twenty-minute intervals
between doses were assessed. The antagonists were allowed
to maintain contact with the tissue for at least 30 min before
eventually repeating the curve of agonists. Time control
experiments showed that a second curve to the agonist was
reproducible. Tetrodotoxin (TTX), atropine, or Nω-nitro-L-
arginine methyl ester (L-NAME) were tested against a
submaximal dose of UDP or UTP. Each preparation was
tested with a single agonist and antagonist, except when
otherwise stated.
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ATP-sensitive P2 receptor desensitization was induced
by prolonged perfusion with ATP (30 μM for 10 min). A
transient relaxation occurred on addition of ATP to the bath
after which the basal tone returned back to the baseline
value and after 10 min ATP response was abolished. UTP
effects were also studied at pH 6.5 Krebs solution, prepared
by adding, to the physiological pH (7.4) solution, 1.0 N
HCl to achieve the desired level. Lastly, UDP and UTP
were tested in the presence of U-73122, a widely used
specific inhibitor of phospholipase C, nifedipine, L-type
voltage-dependent calcium channel blocker, and low
calcium solution.
Solution and drugs
Krebs solution consisted of (in millimolar): NaCl, 119;
KCl, 4.5; MgSO4, 2.5; NaHCO3, 25; KH2PO4, 1.2; CaCl2,
2.5; glucose, 11.1. Solution with low calcium was made by
equimolar substitution with sodium. The following drugs
were used: adenosine 5′-triphosphate (ATP), atropine
sulphate, carbachol, 4-[[4-Formyl-5-hydroxy-6-methyl-3-
[(phosphonooxy) methyl]-2-pyridinyl] azo]-1,3-benzenedi-
sulfonic acid tetrasodium salt (PPADS), indomethacin,{1-[6
((17β-3-methox-yestra-1,3,5 (10)-trien-17-yl)amino)hexyl]-
1H-pyrrole-2,5-dione} (U-73122), L-NAME, nifedipine, 6-
N,N-diethyl-D-b,g-dibromomethyleneATP trisodium salt
(ARL 67156), suramin, tetrodotoxin (TTX), uridine 5′-
diphosphate sodium salt (UDP), uridine 5′-triphosphate tris
salt (UTP), (Sigma-Aldrich, Inc., St. Louis, USA). N,N˝-
1,4-butanediylbis[N′-(3-isothiocyanatophenyl)thiourea
(MRS 2578), 3-(2-oxo-2-phenylethyl)-uridine-5′-diphosphate
disodium salt (PBS 0474), 2-thiouridine 5′-triphosphate
tetrasodium salt (2-thio-UTP), uridine-5′-(γ-thio)-triphos-
phate trisodium salt (UTPγS) (Tocris Cookson Ltd., Avon-
mouth). Indomethacin solution was prepared fresh in 2%
sodium carbonate solution and the pH was adjusted to
7.4. MRS 2578 was dissolved in dimethyl sulphoxide,
U-73122 and nifedipine in ethanol, and further diluted
in Krebs. All the other drugs were dissolved in distilled
water. Control experiments using the different solvents
alone showed that none has effect on the contractility of
the ileum segments. The working solutions were
prepared fresh on the day of the experiment by diluting
the stock solutions in Krebs. Concentrations of the
drugs used were determined from literature.
RNA isolation and RT-PCR
Total RNA was extracted from mouse ileum specimens
devoid of mucosa layer, using PureLink™ RNA Mini Kit
(Invitrogen, Paisley, UK) according to the manufacturer’s
instructions. After quantification by spectrophotometry,
1 μg of total RNA was reverse-transcribed in a final
volume of 50 μl using the High Capacity c-DNA Reverse
Transcription Kit (Applied Biosystems, Foster city, CA,
USA) and the following thermal cycle profile: 10 min at
25°C, 2 h at 37°C, and 5 min at 85°C as described by the
kit. cDNA (100 ng per reaction) was denatured and
subjected to PCR amplification. Each PCR cycle consisted
of denaturing at 94°C for 45 s, annealing at 58°C (P2Y2,
P2Y4 receptors and β-actin) or 56°C (P2Y6 receptor) for
45 s, and extension at 72°C for 1 min. This was repeated
for 35 cycles, followed by extension at 72°C for 15 min.
PCR analysis was performed in triplicate. The oligonucle-
otide primers for mouse P2Y2, P2Y4 and P2Y6 receptors,
and β-actin were as follows: P2Y2: (forward) 5′-
CTCACGCGCACCCTCTACTA-3 ′ , ( reverse) 5 ′-
TCGGGTGCACTGCCTTTCTT-3′; P2Y4: (forward) 5′-
CTTTGGCTTTCCCTTCTTGA-3 ′ , ( reverse) 5 ′ -
GTCCGCCCACCTGCTGAT-3′; P2Y6: (forward) 5′-
GCCCTGTGCTGGAGACCTTC-3 ′ , ( reverse) 5 ′-
CATGGCCCCAGTGACAAACA-3′; β-actin: (forward)
5 ′-CCGCCCTAGGCACCAGGGT-3 ′ , (reverse) 5 ′-
GGCTGGGGTGTTGAAGGTCTCAAA-3′.
The amplimers were separated on a 1% agarose gel
containing 0.5 μg ml−1 of ethidium bromide for visual-
ization, and the gel was scanned under UV light. The
expected length of the PCR products for P2Y2, P2Y4 and
P2Y6 receptors, and β -actin were 548, 427, 226, and
300 bp, respectively. The corrected band intensities of the
specific P2Y receptors obtained using the ImageJ software
(U.S. National Institutes of Health, Bethesda, MD, USA)
were normalized with the corresponding β-actin mRNA
expression. It was ensured that the band intensities of β-
actin mRNA were similar before the comparison of the
expression levels.
Statistical analysis
All data are given as means ± S.E.M. The variable “n”
in the results section refers to the number of animal
preparations on which observations were made. Contrac-
tile responses were expressed as a percentage of the
amplitude of contraction induced by 10 μM carbachol
(CCh). Inhibitory effects were estimated as a percentage of
the decrease of the spontaneous contraction amplitude,
100% corresponding to the total suppression of spontane-
ous contractions. Responses to uracil nucleotides and
related drugs were fitted to sigmoid curves (Prism 4.0,
GraphPAD, San Diego, CA, USA), and EC50 values (with
95% confidence intervals (CIs)) were determined from
these curves. Statistical analysis was performed by means
of Student’s t test or by means of analysis of variance,
followed by Bonferroni’s test, when appropriate. A
probability value of less than 0.05 was regarded as
significant.
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Results
Isolated segments of the mouse ileum displayed spontane-
ous activity consisting of phasic contractions with an
amplitude of 347.2±31.0 mg (n=20) and a frequency of
30.1±3.2 cpm (n=20). Noncumulative additions of UDP
and UTP, at concentrations ranging from 0.3 to 100 μM,
were tested in the continued presence of the ecto-
nucleotidase inhibitor ARL67156 (30 μM), which per se
did not modify spontaneous mechanical activity. UDP
induced a concentration-dependent muscular contraction,
reaching a maximum of 641.5±58.3 mg (n=20) at a
concentration of 100 μM, with an EC50 of 4.1 μM (95%
CIs, 2.3–8.7 μM, n=20) (Fig. 1). Indeed, UTP caused a
concentration-dependent biphasic effect characterized by an
early, transient inhibitory effect, consisting of a transient
reduction of the amplitude of the spontaneous contractile
activity up to the complete abolition (EC50=4.0 μM; 95%
CIs, 2.7–7.2 μM; n=20), followed by muscular contraction
(EC50=4.5 μM; 95% CIs, 1.1–15.5 μM; n=20) (Fig. 1).
The maximal contractile response of administered UTP
(100 μM) was 602.0±24.1 mg (n=20). No evident
relaxation was observed also in preparations subjected to
an initial tension of 500 mg. Indomethacin (10 μM), a
cyclooxygenase inhibitor, TTX (1 μM), neural voltage-
gated sodium channel blocker, atropine (1 μM), muscarinic
receptor antagonist, or L-NAME (100 μM), a nitric oxide
synthase inhibitor, failed to affect the responses to
submaximal doses of UDP and UTP (10 μM each) (Fig. 2).
Pharmacological characterization of UDP responses
UDP excitatory effects were significantly reduced in the
presence of the P2 receptor antagonists, PPADS (50 μM) or
suramin (100μM) (Fig. 3). The effect of PPADS and suramin
appeared to be noncompetitive leading to a reduction in the
maximal response. In addition, the UDP responses were
markedly reduced by MRS 2578 (0.1 μM), noncompetitive
P2Y6 receptor antagonist [22] (Fig. 3). The P2Y6-purinor-
eceptor agonist, PSB 0474 (0.03–10 μM) [23], induced, as
well, a concentration-dependent contraction of mouse ileum
longitudinal muscle (EC50=0.3 μM, 95% CIs, 0.2–0.4 μM,
n=5) (Figs. 3 and 4), antagonized by PPADS (50 μM),
suramin (100 μΜ), or by the P2Y6 receptor antagonist, MRS
2578 (0.1 μΜ) (Fig. 3). None of the antagonists per se had
any effects on the spontaneous activity of mouse ileum.
Pharmacological characterization of UTP responses
UTP inhibitory effects were markedly reduced by PPADS
(50 μM), but not affected by suramin (100 μM) or by the
P2Y6 receptor antagonist, MRS 2578 (0.1 μM) (Fig. 5a).
Fig. 1 Original tracings show-
ing the effects of the UDP and
UTP (100 μM each) on sponta-
neous mechanical activity of the
longitudinal muscle of a mouse
ileum (top). Concentration–re-
sponse curves for the contractile
effects induced by UDP or UTP
and for the inhibitory effects
induced by UTP in the longitu-
dinal muscle of a mouse ileum
(bottom). Experiments were
performed in the continued
presence of the ecto-
nucleotidase inhibitor
ARL67156 (30 μM). Contractile
responses are expressed as a
percentage of the amplitude of
contraction induced by carba-
chol (CCh, 10 μM), whilst
inhibitory responses as a per-
centage of the decrease of the
spontaneous contraction ampli-
tude, 100% corresponding to the
total suppression of spontaneous
contractions. Data are means ±
S.E.M. (n=20)
278 Purinergic Signalling (2012) 8:275–285
Author's personal copy
Indeed, the excitatory effects were significantly antagonized
by PPADS (50 μM), suramin (100 μM), but not by MRS
2578 (0.1 μM) (Fig. 5b). UTPγS (0.03–10 μM), P2Y2/4
receptor agonist, mimicked UTP responses, inducing a
dose-dependent biphasic response characterized by the
early inhibitory effect followed by the excitatory one
Fig. 2 Histograms showing the lack of effect of the cyclooxygenase
inhibitor, indomethacin (10 μM, n=4), the Na+ voltage-gated neural
channel blocker, TTX (1 μM, n=5), the muscarinic receptor
antagonist, atropine (1 μM, n=5), or the NO synthase inhibitor L-
NAME (100 μM, n=5) on the response induced by UDP or UTP
(10 μM each). Experiments were performed in the continued presence
of the ecto-nucleotidase inhibitor ARL67156 (30 μM). Contractile
responses are expressed as a percentage of the amplitude of
contraction induced by carbachol (CCh, 10 μM), whilst inhibitory
responses as a percentage of the decrease of the spontaneous
contraction amplitude, 100% corresponding to the total suppression
of spontaneous contractions. Data are means ± S.E.M. (n=5). The
graphed values for the UDP or UTP bars are the means of the data
obtained before each treatment (n=19)
Fig. 3 Concentration–response curves for the contractile effects
induced by UDP or PSB 0474, P2Y6 selective receptor agonist, in
the longitudinal muscle of a mouse ileum, in the absence or in the
presence of the P2 receptor antagonists, PPADS (50 μM, n=5),
suramin (100 μM, n=5) or of the P2Y6 receptor antagonist, MRS
2578 (0.1 μM, n=5). UDP was tested in the continued presence of the
ecto-nucleotidase inhibitor ARL67156 (30 μM). Data are means ± S.
E.M. and are expressed as a percentage of the amplitude of contraction
induced by carbachol (CCh, 10 μM). The values for the control curves
are the means of the control data obtained before each treatment (n=
15). *P≤0.05 when the concentration–response curves were compared
to those obtained in the respective control condition
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(inhibitory effect: EC50=0.5 μM, 95% CIs, 0.3–0.9 μM;
excitatory effect: EC50=0.9 μM, 95% CIs, 0.3–2.4 μM; n=
4) (Figs. 4 and 5). UTPγS-induced inhibitory effects were
antagonized by PPADS (50 μM), but not by suramin
(100 μM), whilst the contractile effects were significantly
reduced by PPADS (50 μM) and suramin (100 μΜ)
(Fig. 5). MRS 2578 (0.1 μM) was without any effect. 2-
Thio-UTP (0.1–10 μM), P2Y2 selective agonist, did not
cause any significant changes in the muscular activity
(Fig. 4), even in preparation precontracted with 1 μM CCh
(data not shown). Moreover, 2-thio-UTP (10 μM) did not
attenuate or potentiate a subsequent response to UTP.
As previously reported, in a mouse ileum, ATP evoked a
rapid and transient concentration-dependent relaxation,
followed by a contraction at the higher concentrations
[18]. Since in rodents P2Y4 receptors are equally activated
by UTP and ATP [3], we tested the effects of ATP
desensitization on the response induced by UTP. Desensi-
tization of purinoreceptors with ATP abolished the inhibi-
tion of mechanical activity induced by UTP (10 μM),
without affecting the contractile response (Fig. 6). In
addition, due to the reported effects of extracellular
acidification in altering the potency of agonists at P2Y4
receptors in contrast to P2Y2 receptors [24], the effect of
changing the pH was investigated on the response to UTP.
Changing the pH of the Krebs solution from 7.4 to 6.6
resulted in an increase in the inhibitory effect of UTP
(10 μM), leaving the excitatory effect unaltered (Fig. 6).
Lowering the pH to 6, the spontaneous activity of the ileum
segments was destroyed, and the effect could not be
investigated.
Signal transduction mechanisms
As shown in Fig. 7, the responses induced by UDP and
UTP (10 μM each) were significantly antagonized in the
presence of U-73122 (1 μM), a widely used inhibitor of
phospholipase C (PLC). On the contrary, the responses to
UDP and UTP (10 μM each) were preserved in the
presence of nifedipine (0.5 μM) or low Ca2+ solution
(1.25 mM).
Transcripts encoding uracil nucleotide-preferring receptors
in mouse ileum
RT-PCR was used to investigate the expression of mRNA
encoding for P2Y2, P2Y4, and P2Y6, receptors on prepa-
ration. Transcripts encoding each of receptors were found
in our preparation (Fig. 8).
Discussion
Results from the present study indicate the presence, in the
longitudinal muscle of a mouse ileum, of functional UTP-
and UDP-sensitive receptors. Activation of these receptors
induces both excitatory and inhibitory effects and thus
modulates the spontaneous contractile activity. UDP, via
activation of postjunctional P2Y6 receptors, induces mus-
cular contraction. UTP, via activation of postjunctional
P2Y4 receptors, induces inhibition of the spontaneous
contractile activity, whilst via activation of postjunctional
receptors, which cannot be accounted for by the properties
of current molecular identified/characterized P2Y receptors,
induces muscular contraction. All uracil nucleotide-
preferring receptors are linked to the PLC pathway.
The role of the P2Y receptor activated by adenine-based
purines in the control of intestinal motility has been
extensively studied in the last years [7], but so far, only
few studies investigated a possible involvement of uracil
nucleotides [10–12, 14, 25]. Presently known uracil-
sensitive receptors are belonging to the P2Y2, P2Y4, and
P2Y6 subtypes, which show differential sensitivity to UTP
or UDP. P2Y6 is considered to be specific for UDP, whereas
UTP fails to discriminate between P2Y2 and P2Y4.
Data from our experiments indicate that transcripts for
P2Y2, P2Y4, and P2Y6 receptors subtypes are expressed in
the mouse ileum and that both nucleotides are able to
modulate the contractility of the intestinal muscle, via
activation of distinct uracil nucleotide-sensitive receptors.
UDP exerts exclusively excitatory effects, whilst UTP
induces biphasic effects, inhibition of the mechanical
activity followed by muscular contraction. Contractions
Fig. 4 Original tracings showing the effects on the spontaneous mechanical activity of the longitudinal muscle of a mouse ileum induced by the
P2Y2, P2Y2/4, and P2Y6 receptor agonists, 2-thio-UTP, UTPγS, and PSB 0474 (10 μM each), respectively
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generated by UTP and UDP in ileum muscle are identical,
indicating that the tissue responds similarly to UTP and
UDP, as reported in rat mesenteric and basilar arteries [26,
27] or in rat urinary bladder [28].
The sensitivity of the responses to the nonselective
purinergic antagonists, PPADS and suramin was, at first,
determined. As previously reported before, the nonselective
P2 purinoreceptor antagonist PPADS is able to antagonize
equipotently P2Y4 and the P2Y6 purinoreceptor in mouse,
whereas suramin antagonizes the responses to activation of
P2Y2, P2Y6 purinoreceptor, while it is ineffective at the
P2Y4 receptor subtype [3]. Data from our experiments
revealed that the contractile effects induced by UDP were
antagonized by PPADS and suramin, suggesting an
involvement of P2Y6 receptors. A conclusion was corrob-
orated by the antagonism of the response in the presence of
MRS 2578, an insurmountable noncompetitive P2Y6
antagonist and by the observation that UDP effect was
mimicked by the selective P2Y6-receptor agonist, PSB
0474. As expected, activation of P2Y6 receptors in our
preparation induces activation of PLC and increases in
intracellular calcium concentration via release of Ca2+ from
internal stores. We are aware that recently it has been
reported that UDP is an important cognate agonist of the
P2Y14 receptors [4] and that activation of P2Y14 receptors
induces contractile effects on rat isolated stomach [29].
Whether or not UDP effects may be due also to
coactivation of P2Y14 receptors in our preparation have
not been investigated and deserve further experiments.
UTP induced in a mouse ileum an inhibition of the
contractile activity, as reported in other regions of a mouse
intestine [14, 30, 31]. No relaxation was observed although
Fig. 5 Concentration–response
curves for the excitatory and
inhibitory effects induced by
UTP or UTPγS, P2Y2/4 receptor
agonist, in the longitudinal
muscle of a mouse ileum, in the
absence or in the presence of the
P2 receptor antagonists, PPADS
(50 μM, n=5), suramin
(100 μM, n=5) or of the P2Y6
receptor antagonist, MRS 2578
(0.1 μM, n=5). UTP was tested
in the continued presence of the
ecto-nucleotidase inhibitor
ARL67156 (30 μM). Contractile
responses are expressed as a
percentage of the amplitude of
contraction induced by carba-
chol (CCh, 10 μM), whilst
inhibitory responses as a per-
centage of the decrease of the
spontaneous contraction ampli-
tude, 100% corresponding to the
total suppression of spontaneous
contractions. Data are means ±
S.E.M. The values for the con-
trol curves are the means of the
control data obtained before
each treatment (n=10–15).
*P≤0.05 when the concentra-
tion–response curves were com-
pared to those obtained in the
respective control condition
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ileum was able to relax in response of isoprotenerol. This
inhibitory effect was potently antagonized by PPADS, but
not affected by suramin, giving evidence of pharmacolog-
ical interaction with the P2Y4 receptors, since suramin
antagonizes all P2Y receptor subtypes except the P2Y4
receptor subtype [3]. Indeed, UTPγS, P2Y2/4 agonist [32],
but not the P2Y2 selective agonist, mimicked the effect
induced by UTP. The involvement of P2Y4 receptors is
corroborated by the observation that the inhibitory response
to UTP was abolished by desensitization of the receptors by
ATP, since, as previously reported, murine P2Y4 receptors
can be equally activated by ATP and UTP. Moreover, the
inhibitory effect was increased by decreasing the pH of the
medium, which has been shown to potentiate P2Y4 receptor
responses induced by stimulation with UTP [24]. There-
fore, these observations indicate that activation of P2Y4
receptors is responsible for the genesis of the early
inhibition of the contractile activity induced by UTP.
Activation of P2Y4 receptors induces inhibition of the
ileum contractile activity via the PLC pathway, likely
causing a highly directional and local Ca2+ transients who
would increase the open probability of calcium dependent
K+ channels [33, 34].
Indeed, from our results, the pharmacological profile of
UTP contractile responses cannot allow us to allocate them
to the properties of current molecular identified and
characterized P2Y receptors. In fact, the possibility that
UTP may interact per se with P2Y6 receptors can be
excluded since the contractile effects evoked by UTP were
not affected by MRS 2578. The contractile response to UTP
resulted to be antagonized by PPADS and suramin, letting
us hypothesize an involvement of both P2Y2 and P2Y4
Fig. 7 Histograms showing the effects induced on the responses to
UDP and UTP (10 μM each) by U-73122 (1 μM, n=4), a widely used
specific inhibitor of phospholipase C, nifedipine (0.5 μM, n=4), L-
type calcium channel blockers, or low Ca2+ solution (1.25 mM, n=4).
Experiments were performed in the continued presence of the ecto-
nucleotidase inhibitor ARL67156 (30 μM). Contractile responses are
expressed as a percentage of the amplitude of contraction induced by
carbachol (CCh, 10 μM), whilst inhibitory responses as a percentage
of the decrease of the spontaneous contraction amplitude, 100%
corresponding to the total suppression of spontaneous contractions.
Data are means ± S.E.M. The graphed values for the UDP or UTP
bars are the means of the data obtained before each treatment (n=12).
*P≤0.05 when compared to the respective own control
Fig. 6 Original tracings showing the effects on the UTP (10 μM)-induced responses by ATP receptor desensitization and by changing the pH of
the Krebs solution from 7.4 to 6.6. Experiments were performed in the continued presence of the ecto-nucleotidase inhibitor ARL67156 (30 μM)
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receptor activation. As already reported, UTPγS, P2Y2/4
agonist, mimicked the effect induced by UTP, including as
well contractile responses. The observation that P2Y2
selective agonist did not cause any significant changes in
the muscular activity, even in precontracted preparation, did
not allow us to assign a role of P2Y2 in UTP-induced
effects. Moreover, we did not observe any synergic/
antagonist effects between P2Y2 agonist and UTP. Al-
though the sensitivity to PPADS of the contractile
responses could indicate a partial involvement of P2Y4
receptors, the following observations do not corroborate
such a possibility: (1) as previously demonstrated, ATP, in
the mouse ileum, induces by activation of P2Y receptors
only muscular relaxation [18]; (2) desensitization of P2Y4
receptors by prolonged exposure to ATP did not affect
UTP-induced contraction; (3) the contractile response was
not affected by acidification of extracellular medium.
Altogether, these results may allow us to exclude even the
involvement of P2Y4 receptors in the contractile effects
induced by UTP. Therefore, UTP contractile responses
appear to be mediated by atypical UTP-sensitive receptors,
resembling those described in the dorsal spinal astrocytes of
rats [35] and in the superior cervical ganglion neurons of
mice [36]. However, the pharmacological profile of UTP
contractile responses is the same as UTPγS, which, as
already underlined, is nominally a selective P2Y2/4 recep-
tors agonist. Therefore, it is possible also to speculate that,
in our preparations, P2Y4 receptors may directly associate
as either homo- or hetero-oligomers, with other P2Y
receptor subtypes or non-P2Y receptors, to form receptors
with novel pharmacological properties. The structural
propensity of the P2Y4 protein to form homo-oligomers
has been demonstrated in neuronal cells from the central
and peripheral nervous systems [37]. Moreover, UTP-
induced contraction appears to be mediated by G-protein-
coupled receptors activating PLC, leading to increase in
intracellular calcium concentration by release from intra-
cellular stores. The observation that UTP-induced contrac-
tion was preserved in low calcium medium and in the
presence of nifedipine discarding the possibility that UTP
may activate P2X receptor cation channels promoting
calcium influx via nifedipine-sensitive calcium channels,
as reported in rat vascular muscle [38, 39].
Results from the present study suggest also that
uracil-sensitive receptors are located at postjunctional
level, since the activation of neural sodium channels is
not essential for the contractile or inhibitory induced
effects. In addition, neither acetylcholine nor nitric
oxide, nor prostaglandins are involved in the excitatory
or inhibitory effects to pyrimidines due to the insensi-
tivity of the response to atropine, L-NAME or indo-
methacin. Thus, uracil-sensitive receptors may be
located directly on the smooth muscle, although there
is the possibility that they can be expressed also on the
membrane of other cell types composing the gut wall.
For instance, recent studies have suggested that enteric
glia would express P2Y4 receptors which can be the main
functional receptor underlying the purinergic neuron-to-
glia signaling in the enteric nervous system [15, 16].
Moreover, the “fibroblast-like cells,” recently proposed as
new player in the regulation of GI motility, which may
mediate a significant component of the purinergic post-
junctional response in colonic muscles [40], might express
also uracil-sensitive P2Y receptors.
Although defining the precise role of pyrimidines in
regulating intestinal motility will require further inves-
tigation, the present findings imply that studies on
uracil-sensitive P2Y receptors are a potentially promis-
ing target for the treatment of pathological conditions in
the intestinal tract, including inflammation. Large
amounts of extracellular nucleotides are rapidly released
into the extracellular environment at the site of
inflammation [41], and P2Y6 receptors have been reported
to be upregulated in the context of inflammatory insult in
a mouse colon [42].
In conclusion, functional postjunctional UTP- and UDP-
sensitive P2Y receptors are present in the longitudinal
muscle of a mouse ileum. P2Y6 receptors, activated by
UDP, underlie muscular contraction, whilst P2Y4 receptors,
activated by UTP, underlie inhibition of the contractile
activity. We report, also, evidence for the presence of
atypical UTP-sensitive receptors subserving the excitation
of the contractility. All the uracil-sensitive receptors are
linked to the PLC pathway.
Fig. 8 Expression of transcripts encoding the P2Y receptor subtypes,
P2Y2, P2Y4 and P2Y6 in mouse ileum. β-Actin (β-Act) primer was
used as a control for cDNA integrity. A 100 bp DNA ladder was used
as marker
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